S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CUE

Cue Biopharma (CUE) Stock Price, News & Analysis

$1.89
+0.05 (+2.72%)
(As of 03/28/2024 ET)
Today's Range
$1.85
$1.94
50-Day Range
$1.77
$2.84
52-Week Range
$1.70
$5.12
Volume
192,115 shs
Average Volume
262,704 shs
Market Capitalization
$85.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Cue Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
270.4% Upside
$7.00 Price Target
Short Interest
Bearish
9.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
0.47mentions of Cue Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.17) to ($1.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.68 out of 5 stars

Medical Sector

331st out of 938 stocks

Pharmaceutical Preparations Industry

145th out of 423 stocks

CUE stock logo

About Cue Biopharma Stock (NASDAQ:CUE)

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

CUE Stock Price History

CUE Stock News Headlines

What 4 Analyst Ratings Have To Say About Silence Therapeutics
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Cue Biopharma Inc Ordinary Shares
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Cue Biopharma reports Q3 results
Cue Biopharma Inc Ordinary Shares CUE
See More Headlines
Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2023
Today
3/28/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CUE
Fax
N/A
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+270.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-53,010,000.00
Net Margins
-1,358.43%
Pretax Margin
-1,358.40%

Debt

Sales & Book Value

Annual Sales
$1.25 million
Book Value
$1.53 per share

Miscellaneous

Free Float
40,502,000
Market Cap
$85.27 million
Optionable
Optionable
Beta
2.04
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives


CUE Stock Analysis - Frequently Asked Questions

Should I buy or sell Cue Biopharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CUE shares.
View CUE analyst ratings
or view top-rated stocks.

What is Cue Biopharma's stock price target for 2024?

2 Wall Street research analysts have issued twelve-month price objectives for Cue Biopharma's shares. Their CUE share price targets range from $6.00 to $8.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 270.4% from the stock's current price.
View analysts price targets for CUE
or view top-rated stocks among Wall Street analysts.

How have CUE shares performed in 2024?

Cue Biopharma's stock was trading at $2.64 at the start of the year. Since then, CUE shares have decreased by 28.4% and is now trading at $1.89.
View the best growth stocks for 2024 here
.

When is Cue Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our CUE earnings forecast
.

How can I listen to Cue Biopharma's earnings call?

Cue Biopharma will be holding an earnings conference call on Monday, April 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Cue Biopharma's earnings last quarter?

Cue Biopharma, Inc. (NASDAQ:CUE) posted its earnings results on Tuesday, May, 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. The firm had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.30 million. Cue Biopharma had a negative trailing twelve-month return on equity of 99.14% and a negative net margin of 1,358.43%.

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD).

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.73%), Vanguard Group Inc. (4.73%), Dimensional Fund Advisors LP (1.02%), Northern Trust Corp (0.85%), Monaco Asset Management SAM (0.76%) and Stifel Financial Corp (0.43%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri, Daniel R Passeri, Kerri-Ann Millar and Peter A Kiener.
View institutional ownership trends
.

How do I buy shares of Cue Biopharma?

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CUE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners